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Abstract 
Background: Antimicrobial resistance in South Africa is driven by many factors, such as the careless use of 
prescribed antimicrobial medicines and the use of traditional medicines, with the result that there is always the 
danger of misadministration, interaction, and toxicity. This study was conducted in two different public healthcare 
facilities in iLembe District, KwaZulu-Natal Province, South Africa to determine whether any interaction occurred 
among patients attending outpatient departments in selected healthcare facilities in terms of the concurrent use of 
traditional medicines and prescribed antimicrobial medicines.  
Methods: This study was a cross-sectional descriptive study using medical chart reviews. Antimicrobials prescribed 
alone or in association with traditional medicines were assessed and reported using descriptive statistics. Where 
applicable, associations were carried out; a p-value ˂0.05 was estimated as statistically significant. 
Results: A total of 400 outpatients’ medical records were documented from two different municipalities, revealing 
that many participants had viral infections (194/400, 48.5%). Overall, 12% of participants (48/400) had documented 
adverse effects (30/48) and interactions (18/48). A few participants (15/400) used traditional medicines in 
conjunction with prescribed medicines. After adjustment, negative clinical outcomes namely adverse effects and 
interactions were significantly more likely due to the use of traditional medicines (AOR=0.01, 95% CI:0.001-0.05) 
and (AOR=0.21, 95% CI: 0.37-1.23), respectively. 
Conclusions: Traditional medicine was used sparingly in conjunction with prescribed antimicrobials for infectious 
diseases. However, adverse effects and interactions, such as herbal intoxication, persistent rashes, and treatment 
failure, were documented in a few medical records. Further studies are needed to investigate the effects of the 
concurrent use of traditional medicine with antimicrobials or other prescribed medicines from the perspectives of 
traditional healers and biomedically healthcare professionals. [Ethiop. J. Health Dev. 2021; 35(1):58-71] 
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failure, adverse effects 
 
Background  
Antimicrobial resistance (AMR) is the ability of a 
microorganism to withstand the effects of 
antimicrobials, such that AMR reduces the potential 
human health benefit derived from antibiotics and/or 
antiviral medicines (1). Some microorganisms have 
become resistant to multiple antimicrobial classes, 
which means that infectious diseases caused by resistant 
bacteria are now common (2). A report from the World 
Health Organization (WHO) has shown that 30% of 
bacteria are resistant to common antibiotics used to treat 
bacterial infectious diseases (3). AMR is a serious 
burden, with some bacteria and/or viruses becoming so 
resistant that there is either only ‘last resort’ 
antimicrobials or infections cannot be treated (4).  
 
AMR is a leading cause of treatment failure and is 
largely responsible for the reduction in infectious 
disease extermination rates worldwide (5). Infectious 
and non-infectious disease conditions are mostly treated 
with antibiotics, which leads to the indiscriminate use of 
antimicrobials (6). Viruses and bacteria cause a large 
proportion of infectious diseases; bacterial infections 
account for 45% of deaths in Africa and South-East Asia 
(3). Actually, due to antiretroviral therapy (ART), the 
incidence of HIV infection has decreased from 0.40 per 
1,000 people non-infected with HIV/AIDS in 2005 to 
0.26 per 1,000 people non-infected with HIV/AIDS 
worldwide in 2016 (7). Similarly, from 2000 to 2016, 
the incidence of tuberculosis (TB) decreased by 19%, 
from 173 cases per 100,000 population to 140 per 
100,000 population. Despite the increase in the 
incidence of TB infection, drug-resistant TB remains a 
global menace; as a result, of 600,000 registered new 
cases of TB resistant to rifampicin, 490,000 cases were 
multidrug-resistant (8). 
 
South Africa is not an exception to widespread AMR; it 
confronts a triple AMR burden: drug-resistant 
tuberculosis, drug-resistant HIV and antibiotic 
resistance (1). People living with HIV/AIDS (PLWA) 
increased from 6.8 million in 2014 (9) to 7.52 million in 
2018 (10). AMR is driven by many factors in South 
Africa, such as the careless use of prescribed 
antimicrobial medicines and the use of traditional 
medicine (TM), with the result that there is always a risk 
misadministration, interaction, and toxicity (11).  
 
Plants are considered as one of the most promising 
sources for the discovery of new antimicrobial 
medicines; hundreds of plants in the world are used in 
TM for the treatment of viral and bacterial infections and 
other disease conditions by up to 80% of the population 
in Asia, Africa, Latin America, and the Middle East 
(12). In the European Union, 100 million people believe 
in the use of TM (13). It is estimated that 
approximatively 27 million South Africans, including 
PLWA, depend on TM for their primary health care 
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needs (14). This is due to good access to plants, 
affordability, and confidentiality of health information 
between patients and traditional health practitioners, and 
the high cost of synthetic medicines (15). Medicinal 
plants are also believed to combat the specific symptoms 
of diseases, such as weight loss, skin disorders, lack of 
energy, and digestive problems, including a lack of 
appetite, diarrhea, nausea, vomiting, and treatment for 
side effects from antiretroviral medicines, as well as 
dizziness, fungal infections, pain and stomach upsets 
(16,17). Studies from around the world have shown that 
people have used TN concurrently with different 
prescribed medicines. A study in north-east Scotland 
showed that women have the potential to increase the 
risk of postpartum hemorrhage, alter maternal 
hemodynamic and increase the depression of the central 
nervous system between mothers and fetus (18). In 
addition, another study showed that less than 20% of 
participants co-used TM and antiviral medicines; 
however, nearly 80% of participants used TM before 
contracting HIV infection (19). Furthermore, 45% of 
study participants were co-users of conventional drugs 
and herbs, while a significant proportion of general 
health practitioners who co-used herbs with 
conventional drugs for their patients reported potential 
interactions or adverse effects due to the concomitant 
use of anticoagulants and garlic (20). TM is commonly 
used in combination with conventional medicines, 
mainly with satisfactory results, but in some cases, the 
effect of the two treatments can be increased, interacted 
and/or opposed (21). Different patient groups are known 
to use herbal remedies and conventional drugs 
concomitantly (co-use). This poses a potential risk of 
interactions between herbal drugs by changing the 
pharmacokinetics or pharmacodynamics of the drug. A 
study using a broth microdilution method suggested the 
concurrent use of some classes of antibiotics with some 
medicinal plant extracts against infectious diseases 
caused by Escherichia coli (E. coli). However, in the 
same study other medicinal extracts were tested 
concomitantly with some other classes of antibiotics that 
resulted in resistance to E. coli (22). Little is known 
about AMR among patients who co-use prescribed 
medicines, antibiotics or antiviral medicines with TM. 
Individuals may consult both traditional health 
practitioners (THPs) and biomedically trained 
healthcare professionals (BHPs) in relation to bacterial 
and viral infections. However, there is a limited 
knowledge of interactions about the concurrent use of 
TM and prescribed medicines for bacterial and viral 
infections. A study done among HIV patients who used 
concurrently herbal drugs and antiretroviral medicines 
reported that patients were at risk of developing viral 
resistance, treatment failure, and drug toxicity (23). 
 
This study aimed at determining whether any interaction 
could occur among patients attending outpatient 
departments (OPDs) in selected healthcare facilities and 
who used concurrently TM with prescribed 




Study design: This study was a cross-sectional 
descriptive study using medical chart review among 
patients attending OPDs in two public healthcare 
facilities in iLembe District, KwaZulu-Natal Province, 
South Africa. 
 
Study setting: This study was carried out in iLembe 
District, one of 11 districts in the province of KwaZulu-
Natal in South Africa. iLembe is the smallest district 
municipality in the province with a surface area of 3,269 
km2; it is approximately 75km from Durban with a 
population of 630,464 inhabitants (90.8%) were natives, 
(2.4%) white population and (6.8%) were others. The 
majority of the population in the district consists of 
native isiZulu speakers (82%), followed by native 
English speakers (9.6%), native Xhosa speakers (3.3%) 
and others (5.5%) (24). It is located in KwaDukuza on 
the east coast of the province, bordering the Indian 
Ocean, and comprises four municipalities: Mandeni, 
Ndwedwe, KwaDukuza, and Maphumulo. 
 
Figure 1: Map of the study area (www.municipalities.co.za) 
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There are four hospitals in the iLembe Health District, 
namely Montebello District Hospital, Stanger Provincial 
Hospital, Umphumulo District Hospital, and 
Untunjambili District Hospital. This study involved two 
hospitals: the Stanger Provincial Hospital in the 
municipality of KwaDukuza and the Umphumulo 
District Hospital in the municipality of Maphumulo. 
Both hospitals belong to the iLembe health department 
in the public sector.  
 
Figure 1 shows the area where data were collected for 
this study. The map contains two different arrows that 
show the two hospitals (Hospital A and B) where the 
study was conducted. 
 
Sample size calculation assumption: Records or 
medical charts of patients aged 18 years and older were 
systematically sampled from January 2018 to March 
2018. In general, a margin of precision of ±10% requires 
a sample size of approximatively 100, which increases 
to approximatively 400 for a margin of precision of ±5% 
and 10,000 for a margin of precision of ±1%, for an 
expected prevalence of approximately 50% for the 
outcome variable (25). The sample size was determined 
in respect of the calculation method (26), which 
stipulated that the sample size would be 377 for a 
sizeable population of 20,000, with a margin of 
precision of ±5%, 95% CI and within 50% as an equal 
distribution. Accordingly, iLembe District has a 
population size of 630,464. The researcher assumed that 
the sample size for a large population of 630,464 was at 
least 384 (27). The study was oversampled by a 
maximum sample to include 400 medical chart reviews. 
 
Recruitment process and selection of participants: 
Medical chart records of adult patients, aged 18 years 
and above, irrespective of gender, were selected at the 
OPDs of the two selected healthcare facilities, as well as 
at their respective TB and HIV clinics, during clinic 
visiting hours. Patients’ medical records from January 
2017 to January 2018 were assessed and selected 
according to the study’s inclusion and exclusion criteria 
during the data collection period, February to March 
2018. Records of patients who used concurrently TM 
and prescribed antimicrobials, as well as those who 
developed side effects and/or interactions, were 
reviewed in detail.  
 
Data collection technique and instruments: A medical 
chart review was conducted over four weeks between 
February and March 2018. Data from 400 outpatients 
were collected manually by the researcher, since there 
were no computerized records in the OPDs. A data 
extraction form specifically developed specifically for 
the study. The form included the following information: 
patient’s address, age, gender, marital status, 
educational level, language spoken, occupation, as well 
as viral infectious diseases, bacterial and/or fungal 
infectious diseases. Moreover, the details of any 
antimicrobials prescribed alone (antiretroviral, 
antibiotics and/or antifungals) or in association with 
other prescribed medicines, the use of traditional 
medicine, any adverse effects, and interactions 
registered were assessed. The data extraction form was 
prepared in the English language. Thus, all the patient 
information needed for this study was recorded for every 
eligible outpatient in both hospitals.  
 
Statistical analysis: Descriptive statistics using 
frequencies and percentages were used to describe the 
socio-demographic characteristics of study participants. 
Data deriving from medical records using medical chart 
reviews were transferred into Excel spreadsheets, and 
then later analyzed using Statistical Package for Social 
Sciences (SPSS) software, version 25. Categorical data 
were presented as Tables. The prevalence of HIV 
infection, tuberculosis (TB) infections, and other 
respiratory infectious disease were reported as 
percentages, with 95% confidence intervals (95% CIs). 
The prevalence of the use of TM and prescribed 
antimicrobial medicines were also reported as 
percentages, with 95% CIs. Associations between 
variables were carried out using Pearson’s chi-squared 
tests. For multivariate analysis, a binary logistic 
regression analysis (adjusted odds ratio, AOR) was 
used. In addition, a separate multivariate logistic 
regression model was built to determine the association 
between the use of TM and clinical outcomes. A p-
value ≤ 0.05 was considered as statistically significant. 
Logistic regression analyses were used to calculate odds 




Ethical approval to undertake the study was granted by 
the Biomedical Research Ethics Committee of the 
University of KwaZulu - Natal (Reference BE476/17). 
In this the study, no contact was made with participants. 
Medical chart records were reviewed. The findings of 
this study have been reported anonymously – no names, 
no personal identifiers or file numbers have been 
reported to protect the privacy of, and maintain 
confidentiality about, the study participants. 
 
Results 
This study reviewed 400 documented patients’ medical 
records in two different municipalities in iLembe 
District, KwaZulu-Natal, South Africa.  
Socio-demographic characteristics of study 
participants: Table 1 presents the socio-demographic 
characteristics of the study participants. Overall, the 
majority of participants were black African, female 
gender, and unmarried. Most of the participants were 
employed and had attended at least primary school. The 
median age was 33 years old with a standard deviation 
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Prevalence of infectious diseases associated with HIV 
and TB among study participants: Table 2 presents the 
prevalence of HIV, TB and other associated diseases or 
comorbidities among study participants. The majority of 
participants had either HIV infection alone, a co-
infection of HIV and TB, or HIV with other diseases. 























other infections, excluding HIV infection reported 
above. Overall, 17% of participants had other 
respiratory infections excluding TB. Besides HIV 
infection, TB either alone or associated with other 
comorbidities or other infectious diseases were 
documented in almost 7.5% of cases, while the 




















Category Sub-category N (%) [95% CI] 
iLembe District 
Municipality A 200 (50.0) [45-55] 
Municipality B 200 (50.0) [45-55] 
 Total 400 (100) 
Gender 
Female 218 (54.50) [50-60] 
Male 182 (45.50) [41-51] 
 Total 400 (100) 
Race 
Black African 339 (84.75) [81-89] 
Indian 31 (7.75) [5-10] 
Mixed race 18 (4.50) [3-7] 
White 12 (3.0) [2-5] 
 Total 400 (100) 
Occupation 
Employed 228 (57.0) [52-62] 
Unemployed 172 (43.0) [38-48] 
 Total 400 (100) 
Marital status 
Married 62 (15.50) [12-20] 
Unmarried 314 (78.50) [74-82] 
Widowed 24 (6.0) [4-8] 
 Total 400 (100) 
Educational level 
Illiterate 23 (5.75) [4-8] 
Primary school 193 (48.25) [43-53] 
Secondary school 174 (43.50) [39-49] 
Tertiary 10 (2.5) [1-4] 
 Total 400 (100) 
Language spoken 
English and Afrikaans 43 (10.75) [8-14] 
IsiZulu 340 (85.0) [81-88] 
IsiZulu and English 17 (4.25) [2-6] 
 Total 400 (100) 
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Table 2: Frequency of communicable and non-communicable infectious diseases associated with HIV and 
TB 
AOR: Adjusted odds ratio that is obtained from binary 
logistic regression; CI: confidence interval; HIV: human 
immunodeficiency virus. 
 
Documented medicines prescribed (antimicrobial and 
non-antimicrobials) by biomedically trained healthcare 
professionals: Table 3 presents the frequency of 
documented antimicrobial medicines prescribed by 
BHPs. Most of the medical records reviewed for study 
participants contained prescribed antimicrobials, while 
the remainder had prescribed medicines other than 
antimicrobials. 
Overall, 1,497 medicines were identified within study 
participants’ medical chart records. Although the 
majority of medical records referred to cases of 
infectious diseases and the appropriate antimicrobial 
treatment, non-antimicrobial medicines were 
predominantly prescribed in conjunction with 
antimicrobials. Those non-antimicrobials consisted 
mainly of paracetamol in combination with other 
painkillers (paracetamol +codeine + potassium sorbate), 
which accounted for at least 16%. Antimicrobial 
medicines were mainly common antibiotics or 
antifungals, such as Augmentin® (amoxicillin + 
Category Sub-category Frequency of 
documented 
diseases (%) 




HIV infection alone 49 (12.25) 
p ˂ 0.001 
0.073 (0.039-0.14) 
HIV with tuberculosis 61 (15.25) 
HIV with other bacterial infectious diseases 
(pneumonia (3), meningitis (2) and other 
(12)) 
21 (5.25) 
HIV with fungal infectious diseases non-
identified 
6 (1.5) 
HIV with other sexually transmitted diseases 
(10) and three viral infectious diseases 
(shingles (1), genital warts (2)) 
13 (3.25) 
HIV with non-communicable diseases 
(hypertension (6), assault (injury) (5), renal 
failure (5) and other (28)) 
44 (11) 





Tuberculosis infection alone  35 8.75 (6.1-11.4) 
Tuberculosis with other bacterial infectious 
diseases (pneumonia (3), meningitis (2), one 
fungal infection (candidiasis) and one viral 






Tuberculosis with non-communicable 
diseases (acute gastroenteritis (2), asthma (1) 
and two other diseases) 
5 1.25 (0.27-2.23) 





Respiratory infection alone (pneumonia (3), 
upper respiratory tract infection (3), 
pharyngitis (2) and other (6)) 
14 3.5 (1.83-5.17) 
Respiratory infection with other infectious 
diseases: pneumonia with lower respiratory 
tract infection (1), upper respiratory tract 
infection with diarrhea (1), upper respiratory 
tract infection with tinea pedis (1) and other  
diseases (4) 
7 1.75 (0.79-2.71) 
Respiratory infection with non-
communicable diseases (lower respiratory 
tract infection with acute gastroenteritis (4), 
pneumonia with asthma (4) and other 
diseases (35))  
43 10.75 (7.69-13.81) 
Subtotal 64  
Other infectious diseases alone (urinary tract infection (3), 
one herpes simplex, and other infectious diseases alone (26)) 
30 7.5 (5.01-9.99) 
Non-communicable diseases (hypertension (11), diabetes (5) 
and other diseases (47)) 
63 15.75 (12.26-19.24) 
Total 400 100% 
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clavulanate), Bactrim® (sulfamethoxazole + 
trimethoprim), Flagyl® (metronidazole), and 
fluconazole. These were followed by antiretroviral 
medicines in a fixed-dose combination of antiretrovirals 
containing either tenofovir + emtricitabine + efavirenz, 
or abacavir + lamivudine + lopinavir; and finally 
followed by anti-TB medicines consisting of a fixed-
dose combination of Rifafour®, comprising rifampicin 
+ ethambutol + isoniazid + pyrazinamide. 
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Table 3: Documented medicines prescribed (antimicrobials and non-antimicrobials) by BHPs 





tenofovir + emtricitabine + 
efavirenz, or abacavir + 
lamivudine + lopinavir) 
 
FDC (alone)  31 (7.75) FDC (alone)  31 (2.07) 
FDC with Rifafour®, consisting of a fixed-dose 
combination (rifampicin + ethambutol + 
isoniazid + pyrazinamide)  
31 (7.75) FDC (31) with Rifafour® consisting of a fixed-dose 
combination (rifampicin + ethambutol + isoniazid + 
pyrazinamide) (31) 
62 (4.14) 
FDC with other prescribed antibiotics (Augmentin® 
(amoxicillin + clavulanate) (9) and to other medicines 
(74))  
83 (20.75) FDC (83) with other prescribed antibiotics 
(Augmentin® (amoxicillin + clavulanate) (9) and to 
other medicines (74))  
166 (11.08) 
FDC with prescribed antifungals (clotrimazole (3), 
prescribed antibiotics and other prescribed medicines 
(23)) 
26 (6.5) FDC (26) with prescribed antifungals (clotrimazole 
(3), prescribed antibiotics and other prescribed 
medicines (23)) 
75 (5.01) 
FDC with other prescribed medicines (amlodipine (3), 
hydrochlorothiazide (2) and other (14)) 
19 (4.75) FDC with other prescribed medicines (amlodipine 
(3), hydrochlorothiazide (2) and other (14)) 
38 (2.53) 
Other antiviral used (acyclovir) associated with 8 other prescribed medicines 4 (1) Other antiviral used (acyclovir) associated with eight 
other prescribed medicines 
12 (0.80) 
Subtotal 194 (48.5)  384 (25.62) 
Prescribed antibiotics  
Rifafour® (rifampicin + ethambutol + isoniazid + 
pyrazinamide) with other prescribed antibiotics 
(Augmentin® (amoxicillin + clavulanate) (10), 
Bactrim® (sulfamethoxazole + trimethoprim) (8) and 
others (61)) 
79 (19.75) Rifafour® (rifampicin + ethambutol + isoniazid + 
pyrazinamide) with other prescribed antibiotics 
(Augmentin® (amoxicillin + clavulanate) (10), 
Bactrim® (sulfamethoxazole + trimethoprim) (8) and 
others (61)) 
158 (10.55) 
Other prescribed antibiotics used alone: Flagyl® 
(metronidazole) (4), praziquantel (2) and other (13) 
19 (4.75) Other prescribed antibiotics used alone: Flagyl® 
(metronidazole) (4), praziquantel (2) and other (13) 
19 (1.27) 
Other combination between prescribed antibiotics 
(amoxicillin with metronidazole (8), clotrimazole with 
fluconazole (4) and other (52))  
64 (16.0) Other combination between prescribed antibiotics 
(amoxicillin with metronidazole (8), clotrimazole 
with fluconazole (4) and other (52))  
128 (8.55) 
Subtotal 162 (40.5)  305 (20.37) 
Other prescribed medicines: Panado®: (paracetamol + codeine + potassium sorbate) 
(131), pyridoxine (113), multivitamin (49), Brufen® (ibuprofen (43)) and other (472) 
44 (11) Other prescribed medicines: Panado®: (paracetamol 
+ codeine + potassium sorbate) (131), pyridoxine 
(113), multivitamin (49), Brufen® (ibuprofen (43)) 
and other (472) 
808 (53.97) 
Total 400 (100)  1,497 (100) 
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Documented clinical outcomes of the concurrent use 
of traditional medicines and prescribed medicines 
among study participants: Table 4 presents the 
documented concurrent use of TM and prescribed 
medicines among study participants. Overall, very few 
participants used TM with their prescribed medicines 
had clinical outcomes were documented in their 
medical chart records. Seven out of 15 cases of the co-
use of TM and conventional antibiotics/antiviral drugs 
were interactions consisting mainly of treatment failure 
and drug resistance to the first line ARV treatment and 
a persistent rash to conventional treatment, while loss 
of scrotum pigmentation, diarrhea, nausea, vomiting, 
body pain, headache, and renal impairment were the 
main documented adverse effects. Twelve cases were 
documented of drug resistance and treatment failure, 
either from the first line or the second line of ART, 
severe renal impairment, rashes, kidney pain, jaundice, 
painful lower limbs, weakness, and vomiting. 
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    Table 4: Documented clinical outcomes of the concurrent use of TM and prescribed medicines  
Use of TM (N=15) 
 
Non-use of TM (N=385) 












or sulfamethoxazole + 
trimethoprim), Panado® 
(paracetamol + codeine + 
potassium sorbate)  
Herbal intoxication 
(1), treatment failure 
(to the first line) 
Unconsciousness due 
to overdose (1), 











failure (7), either of 
the first line or the 
second line of FDC  
Missed period (1), 
shingles, and 
sores (1), genital 
warts (1), 
vomiting (2), 




stomach cramps  
HIV with TB 
and/or other 
disease 
FDC, Rifafour® (rifampicin 





(amoxicillin + clavulanate 
potassium), multivitamin, 










Sorol Citrate ®, ampicillin, 
prednisolone, clotrimazole 
cream, Flucox® 
(flucloxacillin), acyclovir  
Herbal intoxication 
(1), treatment failure 
(3) and drug 
resistance (to the first 
line ARV regimen) 




Loss of scrotum 
pigmentation (1), 
diarrhea (2), rash 
resistant (2), nausea 
(1), diarrhea (1), body 
pain (1), headache 





FDC, Rifafour® (rifampicin 
+ ethambutol + isoniazid + 
pyrazinamide), 
Augmentin® (amoxicillin + 
clavulanate potassium), 
Bactrim® (co-trimoxazole 
or sulfamethoxazole + 
trimethoprim), norfloxacin, 
pyridoxine, Panado® 
(paracetamol + codeine + 
potassium sorbate), 
dapsone, multivitamin, 
vitamin B Complex, vitamin 
C 
Drug resistance (2) 
and treatment 
failure (1), either of 
the first line or the 
second line of FDC 
Severe renal 
impairment (2), 
rashes (1), kidney 
pain (2), jaundice 
bloods (1), painful 
lower limbs (1), 
weakness (1) , 
diarrhea (1), 
vomiting (2) 
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Rifafour® (rifampicin + 
ethambutol + isoniazid + 
pyrazinamide), pyridoxine, 
Panado® (paracetamol + 
codeine + potassium 
sorbate), multivitamin 














Drug resistance (1) 
and treatment 
failure, either of 
the first line or the 
second line of FDC 
Diarrhea (1), 
vomiting (1), 





butylbromide), ringer lactate 
Herbal intoxication 
(1) 
Abdominal pain (1), 
vomiting (1), body 
weakness (1) 
TB with Acute 
Gastric Enteric 
Rifafour® (rifampicin + 
ethambutol + isoniazid + 
pyrazinamide), 






Citrate ®, Allergex®, 
pyridoxine, Panado® 
(paracetamol + codeine + 
potassium sorbate), 
multivitamin 















Rifafour® (rifampicin + 
ethambutol + isoniazid + 
pyrazinamide), 




Panado® (paracetamol + 
codeine + potassium 
sorbate), vitamin C 
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Association between the use of traditional medicine 
and documented adverse effects and interactions: 
Table 5 presents associations between the use of TM 
and adverse effects and/or interactions. Overall, less 
than 10% of patients had documented adverse effects. 
A few participants had used TM in conjunction with 
prescribed medicines. Seven out of 15 of the co-uses of 
TM and conventional antibiotics/antiviral drugs were 
interactions consisting mainly of treatment failure and 
drug resistance to the first line ARV treatment, and a 
persistent rash to conventional treatment, while loss of 
scrotum pigmentation, diarrhea, nausea, vomiting, 
body pain headache, and renal impairment were the 
main documented adverse effects. Although there is a 
relatively small number of documented cases of 
interactions and adverse effects in this study, there is a 
risk of AMR and treatment failure among patients 
using TM and prescribed medicines concurrently. This 
result may suggest the need for BHPs to communicate 
properly with patients and document information 
accordingly to allow this type of study (medical chart 
review) to pick the information from medical chart 
records of patients in the absence of face-to-face 
interviews and self-reported use of TM by patients. Of 
the 15 participants, 60% were female, 73.33% had 
attended at least primary school, and were employed.  
 
Documented interactions and adverse effects were 
significantly associated with the use of TM in 
combination with prescribed medicines using Pearson 
chi-square (p< 0.001). Using multiple logistic 
regression models, the risk estimate of using of TM 
alongside prescribed medicines was higher among 
females compared to males. After adjustment, 
documented adverse effects and interactions were 
significantly more likely due to the use of TM. 
 
Table 5: Association between the use of traditional medicine and documented adverse effects and 
interactions 
 
AOR: Adjusted odds ratio that is obtained from binary logistic regression, TM: traditional medicine. 
 
Discussion 
This study found that a few participants had a 
documented concurrent use of TM with prescribed 
medicines (15/400, 3.75%). TM was not commonly 
used by the study participants 385/400 (96.25%). This 
finding is in agreement with a study carried out in 
eThekwini municipality (28), which showed a quite 
low use of ARV in conjunction with TM (4.98%). A 
study done by Hughes et al. (2016) revealed that less 
than 20% of participants co-used TM and ARV(19, 
29). In contrast, however, studies done in Nigeria (30) 
and in north-east Scotland (18) indicated a high 
prevalence (69.4% and 44.9%, respectively) of the 
concurrent use of both TM and prescribed medicines. 
According to the WHO (31), this trend may be 
attributed to accessibility, affordability, and the 
availability of TM. Regardless to the total number of 
those who used TM in this study (15/400, 3.75%), 
almost half of them (8/15, 53.33%) had documented 
adverse effects and interactions (8/15) versus 46.67% 
of those who also used TM but without any adverse 
effects or interactions (7/15). Documented cases of the 
concurrent use of TM and prescribed medicines (8/15) 
were associated with those patients who disclosed this 
concomitant use to BHPs and which resulted mainly in 
treatment failure, drug resistance to the first line ARV 
treatment, and renal impairment. The authors believe 
that numbers of documented adverse effects and 
interactions will increase if BHPs communicate 
consistently with their patients. In addition, the authors 
hold the view that there is a risk of AMR and treatment 
failure among patients using TM and prescribed 
medicines concurrently. This has been demonstrated in 
the relatively small number (15/400) of documented 
Variables (N=400) Use of TM (N=15) p-value 
(χ2) 
AOR (95% CI) 
No Yes  Total   
Gender Female 209 (52.25%) 9 (2.25%) 218 (54.5%) 0.886  1.07 (0.3-2.9) 
Male (Ref.) 176 (44%) 6 (1.5%) 182 (45.5%) 
Educational 
level 





182 (45.5%) 11 (2.75%) 193 (48.25%) 
Secondary 
School. 
170 (42.5%) 4 (1%) 174 (43.5%) 
Tertiary (Ref.) 9 (2.25%) 1 (0.25%) 10 (2.5%) 
Documented 
adverse effects 
No  367 (91.75%) 3 (0.75%) 370 (92.5%) 0.000 
 
0.01 (0.001-0.05)* 
Yes (Ref.) 18 (4.5%) 12 (3%) 30 (7.5%) 
Documented 
interactions 
No 374 (93.5%) 8 (2%) 382 (95.5%) 0.000 
 
0.21 (0.37-1.23)* 
Yes (Ref.) 11 (2.75%) 7 (1.75%) 18 (4.5%) 
 Total 400   
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cases. Therefore, the emphasis of authors on the need 
for BHPs to communicate properly with patients and 
document information accordingly to allow this type of 
study (medical chart review), to pick the information 
from medical chart records of patients in the absence 
of face-to-face interviews and self-reported use of TM 
by patients. 
 
Another study where patients used TM (906/1,130, 
80.2%) reported that only 9.6% of them (109/1130) felt 
confident to disclose the use of their TM to BHPs; they 
believed that their BHPs were more knowledgeable 
regarding the safe use of TM and the danger of adverse 
effects and interactions between TM and prescribed 
medicines, which could have been reduced (32). This 
difficulty is justified by other studies which indicate 
that patients do not disclose the use of TM remedies 
without direct questions. Similarly, another study 
where more than half of the study respondents 
(175/321, 54.6%) did not report to their BHPs the use 
of TM in conjunction with prescribed medicines, with 
the reason that BHPs did not ask or it was not important 
to disclose the information to the BHPs and only a 
small number of those who used TM (3/205, 1.5%) 
developed adverse effects, mainly rashes, gastric 
complications and pimples due to the use of TM (33). 
Communication between BHPs and patients on the use 
of TM is important in order to assess patient needs and, 
more importantly, in the assessment of any potential 
adverse effects and interactions.  
 
In this study, there was no statistically significant 
association between use of TM and gender (p=0.886) 
and the use of TM and level of education (p=0.199). 
The majority of those who used TM were female 
participants (9/15, 60%). This was in agreement with 
other studies carried out in Iraq (34) and in Nigeria 
(35), which indicate that 52.9% and 72.4%, 
respectively, of female participants used more TM 
concurrently with their prescribed medicines than 
males. The preponderance of female use of TM in this 
study (9/15) is similar to other studies that report that 
female gender is a predictor of TM use among people 
living with AIDS (19,36). 
 
This study found a few cases of documented adverse 
effects (30/400) and interactions (18/400) as clinical 
outcomes; among those who had adverse effects, 40% 
(12/30) used TM concurrently with prescribed 
medicines, while 38.89% (7/18) had interactions and 
used TM concurrently. After adjustment, documented 
adverse effects and interactions were significantly 
more likely due to the use of TM (AOR = 0.01, 95% 
CI: 0.001-0.05) and (AOR = 0.21, 95% CI: 0.37-1.23), 
respectively. This may suggest that there is a risk of 
having interactions and adverse effects with the 
concomitant use of TM and prescribed medicines. 
These results are in agreement with a similar study 
conducted in Norway (20), which showed that patients 
who used conventional medicines concurrently with 
TM had significantly (p < 0.05) increased odds of 
experiencing adverse effects (AOR 37.5); in the same 
way, McLay et al. (2017) show that pregnant women 
who co-use TM and conventional medicines had 
postpartum hemorrhage and altered maternal 
hemodynamic (18). Interactions between TM and 
prescribed medicines can occur and may lead to 
negative clinical consequences. However, the results 
of this study are in contrast to studies carried out in 
Portugal and around the world which show that 
antimicrobial compounds from plants can be 
synergistic enhancers, in that though they may not 
possess any antimicrobial properties alone, when used 
concurrently with prescribed medicines, they enhance 
the activity of the medicine and co-users of both TM 
and prescribed medicine feel improved quality of life 
(37,38). 
 
This study found a high prevalence of HIV infection 
(47.5%, 190/400). This finding is in agreement with a 
published report on the high prevalence of HIV 
infection in KwaZulu-Natal, as well as the most 
prevalent province (approximatively 26.6%) among 
the top four provinces for HIV (10). Shah et al. (39) 
show that of 404 participants, 311 (77%) had HIV 
infection in KwaZulu-Natal. The South African 
government has highlighted that aspects of poverty in 
townships, such as inadequate sanitation and food, 
unemployment and poor education, violence, and 
crime, are associated with increased HIV transmission 
(40).  
 
This study was a medical chart review; no direct 
contact was made with patients who reported using TM 
and prescribed medicines concurrently. One of the 
strengths of this study is the demonstration that, despite 
the relatively small number of documented cases, there 
is a risk of AMR and treatment failure among patients 
who use both TM and prescribed medicines – patients 
who had bacterial, viral and/or fungal infections 
developed adverse effects and interactions. Some more 
information could have been collected by talking 
directly to patients themselves. The findings of this 
study should be interpreted with caution. They cannot 
be generalized to the entire province of KwaZulu-Natal 
or to South Africa as a whole. Further studies are 
needed in other districts of KwaZulu-Natal and the rest 
of South Africa. There was a difficulty of finding data 
that revealed the type of TM used, since documented 
patient medical records do not highlight such 
information. Hence, studies involving direct 
interactions with patients, BHPs and THPs are 
warranted to gather more information on the problem 
under study.  
 
Conclusions 
The findings from the present study reveal a low 
documented use of TM in conjunction with prescribed 
antibiotic and/or antiviral medicines. In the healthcare 
facilities included in this study, few documented 
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adverse effects and interactions were documented 
among those who used TM and prescribed medicines 
concurrently. Further studies are needed to investigate 
the effects of concurrent use of TM and prescribed 
medicines on antimicrobial resistance and/or treatment 
failure in other parts of South Africa. 
 
Acknowledgments  
Thanks are due to Dr. G. Lopez, Acting CEO of 
Stanger Hospital, Dr. N. N. Gumede, CEO/Medical 
Manager of Maphumulo Hospital, to Dr. Gervais 
Kabeya Lusamba, and to the nursing and 
administration staff of both hospitals for facilitating 
our access to medical records. Mushebenge Aganze 
Gloire-Aime was helpful during the data collection 
period and statistical analysis. The authors 
acknowledge the help of Mr. Zelalem Getahune, the 
biostatistician, for his assistance with data analysis. 
 
Competing interests  
The authors declare that they have no competing 
interests. MGK received a stipend and expenses from 
the College of Health Sciences, University of 
KwaZulu-Natal. However, the college does not impose 
where to publish findings of this study. 
 
Authors’ contributions  
MN conceptualized the study and its design, revised 
the manuscript, and accepted the final version of this 
publication as the senior author. MGK collected data 
and wrote the first draft of the manuscript. All authors 
have read critically the manuscript for its substantial 
intellectual content and approved the final manuscript. 
 
References 
1. Hunt G, Ledwaba J, Salimo A, Kalimashe M, 
Singh B, Puren A, et al. Surveillance of 
transmitted HIV-1 drug resistance in 5 
provinces in South Africa in 2011. 
Communicable Diseases Surveillance 
Bulletin. 2013;11(4):122-4. 
2. Ledingham JGG, Warrell DA (eds.). Concise 
Oxford textbook of medicine. Oxford: Oxford 
University Press; 2000. 
3. World Health Organization. Global 





4. Galea S. SoPH Bulletin. University of 
Michigan; 2015. 
5. Megraud F. Helicobacter pylori and antibiotic 
resistance. Gut. 2007;56(11):1502. 
6. World Health Organization. Combat drug 
resistance: No action today no cure tomorrow. 
World Health Day 2011. WHO; 2011. 
www.who.int/mediacentre/news/statements/2
011/whd_20110407/en/ 
7. Davis SL, Goedel WC, Emerson J, Guven BS. 
Punitive laws, key population size estimates, 
and Global AIDS Response Progress Reports: 
An ecological study of 154 countries. Journal 
of the International AIDS Society. 
2017;20(1):21386. 
8. World Health Organization. World health 
statistics 2018: Monitoring health for the 












11. Fennell CW, Lindsey KL, McGaw LJ, Sparg 
SG, Stafford GI, Elgorashi EE, et al. 
Assessing African medicinal plants for 
efficacy and safety: Pharmacological 
screening and toxicology. Journal of 
Ethnopharmacology. 2004;94(2-3):205-17. 
12. Fyhrquist P, Mwasumbi L, Hæggström C-A, 
Vuorela H, Hiltunen R, Vuorela P. 
Ethnobotanical and antimicrobial 
investigation on some species of Terminalia 
and Combretum (Combretaceae) growing in 
Tanzania. Journal of Ethnopharmacology. 
2002;79(2):169-77. 
13. World Health Organization. Report of the 1st 
meeting of the WHO advisory group on 
integrated surveillance of antimicrobial 





14. Street RA, Stirk WA, Van Staden J. South 
African traditional medicinal plant trade - 
Challenges in regulating quality, safety and 
efficacy. Journal of Ethnopharmacology. 
2008;119(3):705-10. 
15. Ballabh B, Chaurasia OP, Ahmed Z, Singh 
SB. Traditional medicinal plants of cold 
desert Ladakh—Used against kidney and 
urinary disorders. Journal of 
Ethnopharmacology. 2008;118(2):331-9. 
16. Richter M (ed.). Traditional healing and 
human rights in South Africa. XV 
International AIDS Conference, Bangkok; 
2004. 
17. Petzer K, Mngqundaniso N. Patients 
consulting traditional health practitioners in 
the context of HIV/AIDS in urban areas in 
KwaZulu-Natal, South Africa. African 
Journal of Traditional, Complementary and 
Alternative Medicines. 2008;5(4):370-9. 
71     Ethiop. J. Health. Dev 
 
Ethiop. J. Health Dev.2021; 35(1) 
18. McLay JS, Izzati N, Pallivalapila AR, Shetty 
A, Pande B, Rore C, et al. Pregnancy, 
prescription medicines and the potential risk 
of herb-drug interactions: A cross-sectional 
survey. BMC Complementary and 
Alternative Medicine. 2017;17:543. 
19. Hughes GD, Puoane TR, Clark BL, 
Wondwossen TL, Johnson Q, Folk W. 
Prevalence and predictors of traditional 
medicine utilization among persons living 
with AIDS (PLWA) on antiretroviral (ARV) 
and prophylaxis treatment in both rural and 
urban areas in South Africa. African Journal 
of Traditional, Complementary and 
Alternative Medicines. 2012;9(4):470-84. 
20. Djuv A, Nilsen OG, Steinsbekk A. The co-use 
of conventional drugs and herbs among 
patients in Norwegian general practice: A 
cross-sectional study. BMC Complementary 
and Alternative Medicine. 2013;13(1):295. 
21. Fugh-Berman A. Herb-drug interactions. The 
Lancet. 2000;355(9198):134-8. 
22. Darwish RM, Aburjai TA. Effect of 
ethnomedicinal plants used in folklore 
medicine in Jordan as antibiotic resistant 
inhibitors on Escherichia coli. BMC 
Complementary and Alternative Medicine. 
2010;10(1):9. 
23. Mills E, Foster BC, van Heeswijk R, Phillips 
E, Wilson K, Leonard B, et al. Impact of 
African herbal medicines on antiretroviral 
metabolism. AIDS. 2005;19(1):95-7. 
24. KZNHealth SADo. KwaZulu-Natal Health. 
iLembe Health District  
www.kznhealth.gov.za/ilembe.htm. 2017. 
25. Omair A. Sample size estimation and 
sampling techniques for selecting a 
representative sample. Journal of Health 
Specialties. 2014;2(4):142. 
26. Raosoft I. Sample size calculator. 
www.raosoft.com/samplesize.html. 2004. 
27. Machin D, Campbell MJ, Tan SB, Tan SH. 
Sample sizes for clinical, laboratory and 
epidemiology studies. Oxford: John Wiley & 
Sons; 2018. 
28. Mncengeli S, Manimbulu NM, Panjasaram N. 
Concurrent use of antiretroviral and African 
traditional medicines amongst people living 
with HIV/AIDS (PLWA) in the eThekwini 
Metropolitan area of KwaZulu Natal. African 
Health Sciences. 2016;16(4):1118-30. 
29. Lai RPJ, Meintjes G, Wilkinson RJ (eds). 
HIV-1 tuberculosis-associated immune 
reconstitution inflammatory syndrome. 
Seminars in Immunopathology. 
2016;38(2):185-98. 
30. Adibe M. Prevalence of concurrent use of 
herbal and synthetic medicines among 
outpatients in a mission hospital in Nigeria. 
Int J Drug Dev & Res. 2009;1(1):60. 
31. World Health Organization. Promoting the 
role of traditional medicine in health systems: 




32. Johny AK, Cheah WL, Razitasham S. 
Disclosure of traditional and complementary 
medicine use and its associated factors to 
medical doctor in primary care clinics in 
Kuching Division, Sarawak, Malaysia. 
Evidence-Based Complementary and 
Alternative Medicine. 2017:5146478. 
33. Hasan SS, Ahmed SI, Bukhari NI, Loon 
WCW. Use of complementary and alternative 
medicine among patients with chronic 
diseases at outpatient clinics. Complementary 
Therapies in Clinical Practice. 
2009;15(3):152-7. 
34. Kadhim KA, Abbas AN, Hussain SA. Use of 
herbal drugs as alternative medicine: 
Experience of Iraqi patients. Spatula DD. 
2016;5(4):219-25. 
35. Ilomuanya MO, Okubanjo OO, Azubuike C, 
Oguntibeju A, Ajiboye D, Maduka C. 
Evaluation of the frequency of use of herbal 
drugs with concomitant administration of 
highly active antiretroviral therapy and its 
effect on medication adherence in two health 
care facilities in south western Nigeria. 
Journal of AIDS and HIV Research. 
2017;9(1):8-16. 
36. Oreagba IA, Oshikoya KA, Amachree M. 
Herbal medicine use among urban residents in 
Lagos, Nigeria. BMC Complementary and 
Alternative Medicine. 2011;11(1):117. 
37. Freitas E, Aires A, de Santos Rosa EA, 
Saavedra MJ. Antibacterial activity and 
synergistic effect between watercress 
extracts, 2‐ phenylethyl isothiocyanate and 
antibiotics against 11 isolates of Escherichia 
coli from clinical and animal source. Letters 
in Applied Microbiology. 2013;57(4):266-73. 
38. Duggan J, Peterson WS, Schutz M, Khuder S, 
Charkraborty J. Use of complementary and 
alternative therapies in HIV-infected patients. 
AIDS Patient Care and STDs. 
2001;15(3):159-67. 
39. Shah NS, Auld SC, Brust JCM, Mathema B, 
Ismail N, Moodley P, et al. Transmission of 
extensively drug-resistant tuberculosis in 
South Africa. New England Journal of 
Medicine. 2017;376(3):243-53. 
40. Kehler J. HIV and AIDS and STI: Strategic 
plan for South Africa, 2007-2011: 
Department of Health; 2007. 
https://gcwa.unaids.org/sites/womenandaids.
net/files/South-Africa-AIDS-National-
Strategic-Plan-2007-2011-part1.pdf 
